Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Opportunities to Optimize Cancer Policies Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Jul
21
Today In Oncology
Integrating Environmental Health Into Pediatric Cancer Care May Improve Outcomes
Long-Term Outcomes With SABR in Primary Kidney Cancer
Long-Term Follow-up of Postoperative Chemoradiotherapy With Weekly vs Every-3-Week Cisplatin in Head and Neck Cancer
EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma
Mutant KRAS Vaccine for Prevention of Pancreatic Cancer Development Shows Durable Immune Responses
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo